CannMed Coffee Talk

Morgan Keefer is the Senior Accreditation Officer at A2LA where she works with and assesses cannabis testing laboratories across the United States.  Since joining A2LA, Morgan has presented about Laboratory Shopping, Proficiency Testing, and Microbial Testing in the cannabis industry at Cannabis Science Conference, A2LA's Annual Conference and PITTCON. At CannMed 25 she will present “Accredited Methods in Cannabis Testing” which will explore many of the challenges facing cannabis testing labs. During our conversation we discuss:  The variation of cannabis testing regulations across the U.S., and how that creates challenges for multi-state labs and manufacturers. The lack of established testing standards, which leads to inconsistent results across the industry  The role organizations like AOAC and USP play in creating standard methods   How inconsistent testing results affect consumer safety  The lack of testing requirements for consumable hemp products  Thank You to This Episode's Sponsor: McKinney RSA  McKinney is made up of regulatory science veterans who apply lessons learned in the nicotine space to help cannabis manufacturers better understand the toxicological and societal implications of their product.  They do that by Identifying base compounds, extracts, flavors and terpenes, understanding how they interact, and ensuring effectiveness for the intended use. They also provide dosing recommendations and establish guidelines for product consistency.  Learn more at mckinneyrsa.com  Additional Resources NIHC Verify program  A2LA-NIHC Verify Hemp/Cannabis Recognition Program  A2LA Domestic Recognitions  A2LA Public Documents  Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Dr. Dustin Sulak is a traditional osteopathic physician and expert in integrative medicine. His clinical practice in Maine focuses on treating refractory conditions in adults and children. Dr. Sulak is an internationally-renowned expert in medical cannabis, the author of Handbook of Cannabis for Clinicians: Principles and Practice, and co-founder of Healer, a medical cannabis education resource and products company. He serves on the board of directors of The Society of Cannabis Clinicians and is a passionate educator and leader in the medical cannabis field.  Dustin is also a true CannMed veteran, having participated in every CannMed event dating back to our first conference at Harvard Medical School. He returns to CannMed 25 this year and is contributing to multiple sessions, including: The Cannabinoid Hyperemesis Syndrome Panel CannMed Medical Practicum Bridging the Gap: New Findings on the Utility of CBG-Dominant and THC-Containing Hemp Products Morning Mindfulness Session We discuss: Overview of Dustin's oral presentation on CBG and its clinical use in cannabinoid medicine Current research, anecdotal evidence, and mechanisms of CBG's therapeutic effects Insights from a patient survey studying CBG and THC usage patterns, dosages, and outcomes How the 2018 Farm Bill increased patients' access to THC-containing products Using cannabinoids, especially low-dose THC and CBG, to manage dementia symptoms. Survey data on using ketamine to treat depression and pain Thanks to This Episode's Sponsor: Healer  Healer is a trusted, physician-developed medical cannabis brand founded to address the challenges of helping patients and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer's distinctive product formulations and educational material are based on the work of leading cannabis clinician, Dr. Dustin Sulak, D.O.  Learn More at healer.com Additional Resources  Healer.com  HealerCBD.com Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters – –  Review the Podcast CannMed Archive

Zamir Punja, PhD is a Professor of Plant Biotechnology at Simon Fraser University in Canada. His research interests include the etiology and management of plant diseases on vegetable and horticultural crops, and the applications of plant biotechnology for disease management. Since 2018, his work has shifted to researching cannabis, where his group has described a range of previously unreported pathogens affecting the crop and has evaluated various methods for disease management. At CannMed 25, Zamir will present his team's latest work investigating the microbiome of cannabis and hemp plants. Using Next-Generation Sequencing and microscopy, his team identified diverse fungi, yeasts, and bacteria across plant tissues. Their study reveals that cannabis plants host abundant microbial endophytes, which can impact plant health and product quality. Findings also highlight the influence of growing substrates and biocontrol agents on the cannabis microbiome. During our conversation, we discuss: What is the microbiome and how do microbial endophytes affect plant health Identification of common microbes found in cannabis samples, including Penicillium and Fusarium Whether meristem tissue culture is a viable microbial sterilization method The influence of sterilized vs. non-sterilized growing media How growers can use microbiome analysis for early interventions Insights into beneficial fungi like Trichoderma and Mycorrhizae Future research questions on microbial balance and seed microbiome engineering And More Thanks to This Episode's Sponsor: GrowDefender GrowDefender provides long-lasting antimicrobial protection for indoor cultivation and processing spaces. Using patented Goldshield® technology, their EPA-registered, water-based products protect surfaces from mold, mildew, bacteria, and fungi for up to 90 days. Safe, non-toxic, and easy to apply, GrowDefender helps growers reduce contamination, protect crops, and maintain cleaner, healthier environments. Learn more at growdefender.com Additional Resources Endophytes in Cannabis sativa: Identifying and Characterizing Microbes with Beneficial and Detrimental Effects on Plant Health - https://pmc.ncbi.nlm.nih.gov/articles/PMC12030312/ Exploring the fascinating development of cannabinoid-producing trichomes - https://youtu.be/Avhr8XjsBTU?si=nbYpjuoMMnKVqF6X Register for CannMed 25 - https://cvent.me/emBPno Meet the CannMed 25 Speakers and Poster Presenters - https://cannmedevents.com/speakers/ - Review the Podcast - https://podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804 CannMed Archive - https://cannmedevents.com/cannmed-video-archives/

Dr. Dedi Meiri is an Associate Professor at the Technion Institute where he heads the Laboratory of Cancer Biology and Cannabinoid Research. The lab investigates the vast therapeutic potential of secondary metabolites from cannabis and other herbs, algae, and psychedelic mushrooms; and reveals how these naturally occurring metabolites affect various types of cancer, inflammatory diseases, and disorders of the nervous system Dr. Meiri is also highly involved in governmental regulations and is a residing member in several Israeli Ministry of Health committees that seek to advance the fundamental understanding of optimal cannabis and other psychedelic plant usage and curtailing adverse effects. At CannMed 25, Dedi will present "Cannabis as a Therapy Across Diverse Cancer Types: Milestones and Insights from a Decade of Research", which will discuss his lab's work investigating whether Cannabis can serve as a primary pharmaceutical treatment for cancer. We discuss: The wide range of clinical applications for cannabis medicine, including cancer, epilepsy, sleep disorders, Alzheimer's, and women's health issues like endometriosis. How cannabis' entourage effect challenges the traditional one-drug-one-target model. How many powerful cannabinoids are overlooked by standard lab testing methods—even though they exist in significant quantities and show therapeutic potential. Israel's Medical Cannabis Model, which treats cannabis like a pharmaceutical, with prescriptions, clinical oversight, and growing physician acceptance. The goal is to provide evidence-based, accurate treatments that tailor cannabis therapies to specific health conditions and individual needs. Thanks to This Episode's Sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more. Learn more at trustedcannanurse.com Additional Resources Dedi Meiri Publications on Google Scholar Dedi Meiri on Linkedin Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Michael Petersen has over 38 years of experience as a researcher and mentor in both the private and public plant biotech space. He has over 50 issued patents and his work in plant transformation and gene expression is a passion. Mike has worked on many genetic engineering/editing contracts with entities across the globe, and he now focuses on innovative hemp research. At CannMed 25, Mike will share his team's latest efforts to transform cannabis and hemp plants using gene editing and genetic engineering in a presentation titled, “Creation of Novel Traits Through Genetic Engineering and Editing of Cannabinoid, Terpene, and Flavonoid Pathways in Cannabis sativa” During the conversation, we discussed: The difference between gene editing and genetic engineering How gene editing and genetic engineering methods have changed over the years Potential applications of gene editing and genetic engineering in cannabis and hemp Benefits and challenges versus traditional breeding The Wisconsin Crop Innovation Center's gene editing service, which is available to researchers and cultivators Thanks to This Episode's Sponsor: Kannapedia.net Kanapedia.net is the world's most comprehensive cannabis genomic library, featuring more than 2,200 genomic reports on cannabis and hemp varieties from around the globe. Kannapedia.net reports are easily searchable and contain Visualizations and Variant Tables that highlight high-impact variants in genes of interest. For example, you can see a report for the Badger G variety that Mike Petersen's team edited to break the CBDA synthase gene. In fact, you can see the drop out in the CBDA coverage chart on that report. . Visit Kannapedia.net to learn more. Additional Resources Wisconsin Crop Innovation Center Email Mike Michael Petersen on Linkedin Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Israel Gasperin is a visionary entrepreneur, engineering scientist and the founder of Zentrela, a company dedicated to transforming cannabis research through advanced neurotechnology and AI. Under Israel's leadership, Zentrela developed the Psychoactive Effect Level (PEL) metric, an innovative EEG-based measure capable of objectively assessing cannabis products' psychoactive potency. By combining wearable EEG technology with AI-driven EEG analysis, the PEL metric provides cannabis producers, researchers, and regulators with a non-invasive and cost-effective way to quantify product effects and maintain quality control.  At CannMed 25, Israel will share results from over 10,000 EEG scans of consumers using a wide range of cannabis products in his oral presentation titled “Cannabis Effect Research Driven by EEG Technology and Machine Learning”. During our conversation, we discuss:  How Zentrela's wearable EEG technology got its start measuring drowsiness in truck drivers   The unreliability of consumer feedback with regards to cannabis product effects  How the PEL metric was created to measure the unique psychoactive effects of cannabis How producers can use PEL to objectively measure the quality and effectiveness of cannabis products beyond cannabinoid percentages  Research findings that show THC% and PEL% are not directly correlated  and more  Thanks to This Episode's Sponsor: The DENT Institute With more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson's, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute. Learn more at dentinstitute.com Additional Resources Zentrela Website Israel Gasperin on LinkedIn Use of a Novel EEG-Based Objective Test, the Cognalyzer®, in Quantifying the Strength and Determining the Action Time of Cannabis Psychoactive Effects and Factors that May Influence Them Within an Observational Study Framework Sensitivity, Specificity and Accuracy of a Novel EEG-Based Objective Test, the Cognalyzer®, in Detecting Cannabis Psychoactive Effects Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Shawna Vreeke, PhD is Head of Research at True Terpenes, where she is instrumental in developing and maintaining the rigorous safety and quality protocols the brand is known for. Shawna is an active advocate for science-based safety parameters to protect consumer health and has worked with policymakers to implement sensible regulations to protect public health and maintain access to regulated cannabis products. She has multiple peer-reviewed papers on vape safety, and most recently, her work has been adopted into two ASTM global standards. At CannMed 25 Shawna will present Toxicological Risk in Cannabis Vapes: Exogenous Additives and Their Implications for Consumer Safety. It will highlight specific higher-risk ingredients and identify how prevalent they are in vaporization products currently in the cannabis market.  During our conversation we discussed:  The main components of cannabis vape products  How and why exogenous ingredients are added to vape products How toxicological risks are evaluated based on hazard and exposure level  Why one can't assume that safe food ingredients are also safe for inhalation  Why risk-assessment based regulations are a better approach to outright bans on flavors and more  Thank You to This Episode's Sponsor: McKinney RSA  McKinney is made up of regulatory science veterans who apply lessons learned in the nicotine space to help cannabis manufacturers better understand the toxicological and societal implications of their product.  They do that by Identifying base compounds, extracts, flavors and terpenes, understanding how they interact, and ensuring effectiveness for the intended use. They also provide dosing recommendations and establish guidelines for product consistency.  Learn more at mckinneyrsa.com  Additional Resources True Terpenes website Connect with Shawna Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Dr. Staci Gruber is the Director of the Cognitive and Clinical Neuroimaging Core at McLean Hospital's Brain Imaging Center and an Associate Professor of Psychiatry at Harvard Medical School. Dr. Gruber launched Marijuana Investigations for Neuroscientific Discovery (MIND) in 2014, the first ever program of its kind designed to clarify the long-term impact of medical cannabis use. MIND supports numerous projects that aim to address the impact of medical cannabis on a number of important variables including cognition, brain structure and function, clinical state, quality of life, pain, sleep, and other health-related measures. As director of MIND, Dr. Gruber has generated major contributions to the field as the first to assess medical cannabis patients longitudinally, first to acquire neuroimaging data in medical cannabis patients, and as Principal Investigator of the first clinical trial of a full-spectrum, high-cannabidiol (CBD) product, which she specifically formulated to treat anxiety. Additional, novel clinical trials have been approved and are pending or currently underway. At CannMed 25 Staci will share findings from those clinical trials as an oral presenter. https://cannmedevents.com/staci-gruber-phd/ Topics Discussed: Key findings from the MIND Program's longitudinal studies on medical cannabis use (improved cognitive performance and reductions in pain, anxiety, and sleep disturbances) Ongoing clinical trials the MIND Program is conducting on anxiety, bipolar disorder, and Alzheimer's The Women's Health Initiative at MIND (WHIM) investigating cannabis for gynecologic pain, menopause, and endometriosis Concerns about mislabeled cannabis products and unregulated hemp-derived products and more! Thanks to This Episode's Sponsor: Healer Healer is a trusted, physician-developed medicinal cannabis brand founded to address the challenges of helping people and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer Hemp products are available nationwide and include a step-by-step usage guide and response tracker. Healer's distinctive product formulations and education are based on the latest research and work of leading cannabis clinician, Dr. Dustin Sulak, D.O. Visit Healer.com or HealerCbd.com Additional Resources https://www.drstacigruber.com Social Media: @DrStaciGruber on X and Instagram Register for CannMed 25 Meet the CannMed 25 Speakers Review the Podcast CannMed Archive

Dr. Punya Nachappa is an Associate professor at Colorado State University in the Department of Agricultural Biology. Her research program focuses on understanding the interactions between plants and insect vectors to manage plant pests and diseases in hemp. At CannMed 25, Punya will present "Biology and Management of Hop Latent Viroid", which will describe the impact of HLVd on hemp yield and cannabinoids, explain how thrips and aphids transmit the viroid, and evaluate the efficacy of using chemical elicitors to control HLVd infections. During our conversation, we discussed: How Hop Latent Viroid has been reported in every hemp-growing state in the US and Canada How HLVd spreads through infected clones, mechanical contact, seeds, and insect vectors like aphids and thrips. Possible reasons why hemp varieties appear more resistant than cannabis varieties (i.e., genetic diversity and environmental factors) The tradeoffs associated with using chemical elicitors on infected plants: increased yield, but reduced cannabinoids. Strategies for preventing HLVD spread, including strict sanitation, insect monitoring, frequent testing, and breeding for genetic resistance. Thanks to This Episode's Sponsor: Advanced Nutrients. Founded in 1999, Advanced Nutrients was the first to develop a complete nutrient system that unlocks the true genetic potential of the cannabis plant. Since its inception, the brand has introduced more than 50 innovations to the cultivation community and continues to revolutionize the space through proprietary scientific discoveries.  Learn more at AdvancedNutrients.com Additional Resources - Nachappa Lab Website (https://www.nachappalab.com/) - Register for CannMed 25 (https://cvent.me/emBPno) - Meet the CannMed 25 Speakers (https://cannmedevents.com/speakers/) - Review the Podcast (https://podcasts.apple.com/us/podcast/cannmed-coffee-talk/id1504218804) - CannMed Archive (https://cannmedevents.com/cannmed-video-archives/)

Dr. Michelle Peace is an internationally recognized forensic toxicologist and a Full Professor in the Department of Forensic Science at Virginia Commonwealth University. The National Institute of Justice has funded her team to study the proliferation of semi-synthetic THC analogs in the unregulated market and define their relevant biomarkers. Her work impacts public health and public safety policies and initiatives. At CannMed 25 Michelle will present “Why Some People “Green Out”? The Analysis of Unregulated “Hemp-derived” Cannabis Products”. Her team used a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to analyze unregulated hemp products. All the products they analyzed were mislabeled in some way, either misrepresenting the cannabinoids contained therein or their concentrations.  During our conversation we discuss What has caused the rise of semi-synthetic cannabinoids in the market?  How Michelle got involved testing unregulated hemp and cannabis products  Some of the adverse events that have occured from consuming semi-synthetic cannabinoids  How the LS-MS/MS method allows Michelle's team to see compounds other labs can't   How consumers can protect themselves from mislabeled products Whether federal legalization of cannabis would eliminate the semi-synthetic market  Thanks to This Episode's Sponsor: PRICH Biotech PRICH Biotech, Corp. is a vertically integrated company dedicated to the cultivation, manufacture and dispensing of medicinal Cannabis in Puerto Rico.  With over 500,000 square feet of state-of-the-art facilities, Prich uses the highest standards of agricultural and manufacturing practices to guarantee the highest standard of medicinal cannabis. Their mission is to offer a natural and unique experience through medicinal cannabis that raises the patient's well-being and quality of life. Learn more at prichbiotech.com.  Additional Resources Register for CannMed 25 Meet the CannMed 25 Speakers Review the Podcast CannMed Archive

Dr. Nicole Gauthier is a Professor and Extension specialist at the University of Kentucky.  Her program focuses on disease management of specialty crops including fruits, vegetables, and hemp.  In her Extension role, she develops educational and outreach programs to help growers manage disease through identification, understanding of pathosystems, and integration of management strategies. Her research program focuses on a range of hemp diseases, including Fusarium head blight, as well as stand establishment and seedborne transmission.  Dr. Gauthier's resources can be found at plantpathology.ca.uky.edu/extension/publications, on Facebook and Twitter at @KYPlantDisease, and on YouTube at @NicoleGauthier.  Nicole's team at the University of Kentucky recently published a fact sheet about Fusarium head blight in hemp plants, which caught my eye considering many of the cultivators we work with at Medicinal Genomics struggle with that pathogen. During our conversation, we discuss: The financial impact of fusarium on Hemp and cannabis crops The public health concerns due to Fusarium's production of harmful mycotoxins How growers often misidentify Fusarium head blight as Botrytis due to similar symptoms, leading to ineffective management strategies. Environmental conditions that increase the likelihood of a Fusarium infection Challenges for prevention and management, including a lack of effective fungicides and resistant cultivars Future Research to understand Fusarium spread, genetic resistance, and management techniques Thanks to this episode's Sponsor: Rare Earth Genomics. Rare Earth Genomics is a dynamic partnership formed with Texas A&M AgriLife, one of the world's leading research institutions, to accelerate hemp research and create tools for farmers. Their mission is to increase the likelihood of a successful harvest for farmers through genetic analysis and rigorous environmental testing of vigorous cultivars. Learn more at rareearchgenomics.com Additional Resources UK Plant Pathology resources and publications USDA hemp multistate group (S1084) resources page UK hemp website Register for CannMed 25 Meet the CannMed 25 Advisory Board Review the Podcast CannMed Archive

Ed Leclere and David McKillop have teamed up to create High Science, a new TV series premiering on YouTube TODAY November 27th featuring Medicinal Genomics and CannMed. David is an Emmy-award-winning producer with an impressive background in creating hit shows like Duck Dynasty and Pawn Stars. He brings his storytelling expertise to the cannabis space, teaming up with Ed Leclere to launch a show that's as entertaining as it is informative. High Science promises to take viewers on a journey through the world of cannabis, focusing on its therapeutic potential, the people who grow it, and the science that drives it forward. During our conversation, we discuss: Ed's personal health journey and how it inspired the show's creation The show's goal to make the medical science of cannabis more accessible to the public and reduce cannabis stigma. The challenges that cannabis entrepreneurs face in the form of strict regulations, financial challenges, and a thriving black market. How the series uses personal storytelling to balance education and entertainment. Why YouTube was chosen for its global reach and creative freedom compared to traditional networks. A glimpse into future seasons which may explore other plant medicines, such as mushrooms. Thanks to This Episode's Sponsor: High Science TV High Science TV shares the lively exploits of colorful characters around the world, trailblazing all things cannabis in pursuit of the modern-day gold rush. Father/son show hosts Rich Batenburg Jr. and Richard “Rick” Batenburg III explore legendary seed gurus, relentless cultivators, expansive growers, pioneering product makers and imaginative dispensary owners as they break the barriers of this new frontier. The storytelling unmasks the mystical powers of the ancient cannabis plant and its innumerable uses through dynamic entertainment. High Science premieres on YouTube November 27th at YouTube.com/@HighScienceTV. Additional Resources Watch High Science HighScience.com Register for CannMed 25 Meet the CannMed 25 Advisory Board Review the Podcast CannMed Archive

Kevelin Barbosa-Xavier is a PhD student in Plant Biotechnology at Universidade Estadual do Norte Fluminense Darcy Ribeiro (UENF) where she conducts research under the supervision of Thiago Motta Venancio. She is a computational biologist, investigating the genes and gene networks involved in plant secondary metabolic pathways and fiber production, specifically in the Cannabis sativa species. Kevelin and her team recently published a study titled Cannabis Expression Atlas: a comprehensive resource for integrative analysis of Cannabis sativa L. gene expression, along with a free online tool to help researchers analyze genomic sequence data. We discussed: The team's main objectives in creating the Cannabis Expression Atlas How our understanding of cannabis genomics compares to other commercial crops How gene expression data can advance plant breeding and genetic engineering Potential applications of the Cannabis Expression Atlas in commercial cannabis cultivation and more Thanks to This Episode's Sponsor: Medicinal Genomics Medicinal Genomics (MGC) uses its unmatched knowledge of the cannabis genome and the microbes affecting cannabis plants to create diverse testing solutions that improve crop yield, accelerate breeding programs, and ensure product safety. Growers and breeders use MGC's cannabis genome sequencing services to identify novel traits, stabilize genetics, and protect intellectual property. Additionally, Kannapedia.net provides bioinformatics and blockchain certification for cultivar authenticity. Learn more at medicinalgenomics.com Additional Resources Cannabis Expression Atlas: a comprehensive resource for integrative analysis of Cannabis sativa L. gene expression Cannabis Expression Atlas Register for CannMed 25 Meet the CannMed 25 Advisory Board Submit Your Abstract for CannMed 25 Review the Podcast CannMed Archive

Laura Barrett, MBA, BSN, RN, known as “Nurse Laura,” is the Founder and Executive Director of the National Clinical Director Consortium and the Owner and Operator of Ask Nurse Laura. She serves on the boards of several non-profits, including the Connor Sheffield Foundation. Nurse Laura is dedicated to educating individuals and groups about cannabis and psychedelic medicine options, whether in small settings or large conference auditoriums.  Additionally, she is part of the teaching faculty at the University of Maryland's School of Pharmacy and New York University's Business School where she teaches multiple courses - including the collaborative development of a psychedelic elective course for the Masters of Cannabis Science and Therapeutics program. She also conducts training sessions with healthcare provider groups and nursing organizations, delving into state-specific regulations, products, and access for providers. Collaborating closely with pharmacists, providers, and fellow nurses in the cannabis industry, Nurse Laura promotes valuable educational resources for healthcare professionals, patients, and dispensary staff. Her mission is to enhance consistency and reliability in the educational opportunities available, specifically in healthcare. Nurse Laura has hands-on experience in various aspects of the cannabis industry, including cultivation, processing, dispensary operations, sales, marketing, and compliance. She emphasizes the importance of understanding laws and regulations, reviewing scientific research, and gathering patient data to create accessible presentations that support public health. Her balanced approach to cannabis and hemp integrates them into a holistic view of wellness.  Nurse Laura stays informed about current research on the medicinal use of cannabis and psychedelics to help patients and her peers assess the benefits and risks unique to everyone. She crafts tailored care plans incorporating well-established practices that she and her industry peers aim to standardize. Beloved by her patients for their improved health and respected by fellow practitioners for her perseverance and dedication, Nurse Laura is committed to advancing the evolving field of plant medicine therapeutics. Laura is currently working with the Connor Sheffield Foundation on an observational research study about the use of cannabis to treat symptoms of Post Traumatic Stress Disorder (PTSD).  During our conversation we discuss:  How cannabinoids affect trauma responses and support cognitive therapy  Details about the research study, including who should participate and how data will be collected  How patients use different routes of administration, cannabinoid ratios, and dosages to manage certain symptoms  The challenges of doing cannabinoid research and the need for standartization across the US  and more  Thanks to This Episode's Sponsor: McKinney RSA McKinney is made up of regulatory science veterans who apply lessons learned in the nicotine space to help cannabis manufacturers better understand the toxicological and societal implications of their product.  They do that by Identifying base compounds, extracts, flavors and terpenes, understanding how they interact, and ensuring effectiveness for the intended use. They also provide dosing recommendations and establish guidelines for product consistency.  Learn more at mckinneyrsa.com  Additional Resources Connor Sheffield Foundation PTSD Research Study Link AskNurseLuara.com National Clinical Director Consortium Cannabinoid modulation of brain activation during volitional regulation of negative affect in trauma-exposed adults Register for CannMed 25 Meet the CannMed 25 Advisory Board Submit Your Abstract for CannMed 25 Review the Podcast CannMed Archive

With a BSc. in molecular biology and an MSc. in physiology, Liz has studied the human body through many lenses. The focus of her PhD program (Pharmacy) is to explore disorders that have directly impacted her life in the world of professional contact sports, and how cannabinoid products could potentially play a role in these.  As a member of the clinical trial team that was recently awarded funding from the NFL to study cannabinoids in concussion and pain, she is excited to bring new data to the literature exploring cannabinoids and athletics. Liz and her team recently published an extensive literature review titled Cannabinoid Therapy in Athletics: A Review of Current Cannabis Research to Evaluate Potential Real‑World Cannabinoid Applications In Sport, which establishes a foundation for their future research.   During our conversation, we discussed:  How Liz became interested in the therapeutic potential of cannabinoids Published literature that supports using cannabinoids for neuroinflammation and neurodegenerative disorders Her team's collaboration with the NFL and ongoing clinical trials focused on neuroinflammation and recovery in athletes, particularly after concussions Current use of cannabis in athletics and how sports organizations are changing their policies  Future directions of research  and more  Thanks to This Episode's Sponsor: The DENT Institute With more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson's, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute. Learn more at dentinstitute.com Additional Resources Cannabinoid Therapy in Athletics: A Review of Current Cannabis Research to Evaluate Potential Real‑World Cannabinoid Applications In Sport trainwithmaryjane.com Train with Mary Jane on Instagram Submit Your Abstract for CannMed 25 Review the Podcast CannMed Archive

Megan Mbengue is the revolutionary force behind Trusted Canna Nurse. With over 10 years of nursing experience in diverse fields like oncology, labor delivery, and hospice care, she brings a unique perspective to her practice. She also holds national certifications in three nursing specialties and a Master of Science degree in Medical Cannabis Therapeutics. Codi Peterson is the Chief Science Officer at The Cannigma and a practicing pharmacist with a passion for cannabis-based medicine. Given his diverse pediatric pharmacy experience and knack for educating, he aims to educate as many as possible about the medicinal potential of cannabis Codi and Megan have launched a new IRB-approved survey through the University of California that aims to better understand the signs, symptoms, and challenges of CHS. They want to understand the key indicators of this condition, hear about any remedies that work, and learn more about navigating healthcare as a CHS patient.  If you or someone you know has suffered from CHS (and are over 18), please take a moment to fill out their survey. Not only will you be helping this vital research, but participants will be entered into a drawing to win one of three $100 gift cards. I've put a link in the show description so it's easy to find.  During our conversation, we discuss:  Overview of CHS symptoms   Early Symptoms and the Prodrome Phase  Clinical experiences treating CHS patients  The Potential Causes   Challenges in diagnosing CHS  Treatment and Abstinence from Cannabis  Thanks to This Episode's Sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more.  Learn more at trustedcannanurse.com  Additional Resources Take the CHS Survey! Cannabinoid Hyperemesis Syndrome What You Need to Know [Video] what-is-chs.com Connect with Megan (Instagram, LinkedIn) Connect with Codi (Instagram, LinkedIn) Submit Your Abstract for CannMed 25 Review the Podcast CannMed Archive

Justin Esquivel is CEO & Geneticist, Green Luster Phenos™ and has been an influencer and leader in the cannabis industry for 15 years. Esquivel was the head grower and geneticist of an indoor commercial-scale cultivation operation back in 2012.  Justin has consulted with over 100 cannabis facilities, 72 of which operate commercial canopies.  Esquivel provides home growers with pest and bacteria-resistant genetics in seed and breeders' cut form on a global scale!  He brings standard operating procedures to a gold standard.  His one-of-a-kind approach to plasticity breeding has sparked tons of interest across the globe.  Esquivel also specializes in Cannabis Tissue Culture & Selective Homozygous Breeding, enabling his company to bring exotic tailored offspring to growers globally!During our conversation, we discuss:  Justin's background in traditional ag and how that applies to cannabis  How he uses tissue culture to store genetics and eliminate pathogens  The process for creating stable cannabis varieties How purposely introducing pests into the breeding room helps select for resistance traits  The application of analytical tools, such as PCR, HPLC, and marker-assisted breeding  Thanks to this episode's Sponsor: Rare Earth Genomics.  Rare Earth Genomics is a dynamic partnership formed with Texas A&M AgriLife, one of the world's leading research institutions, to accelerate hemp research and create tools for farmers. Their mission is to increase the likelihood of a successful harvest for farmers through genetic analysis and rigorous environmental testing of vigorous cultivars.  Learn more at rareearthgenomics.com  Additional Resources:  greenlusterphenos.com Review the Podcast CannMed Archive

Dr. John Streicher is a Professor in the Department of Pharmacology in the College of Medicine at the University of Arizona. He has built a long-term research program focused on finding improved treatments for pain. This has encompassed multiple approaches over the years, including testing cannabinoid and non-cannabinoid constituents of Cannabis sativa, identifying new ways to target opioid receptor signaling, and identifying new receptor targets in the body for pain relief. His lab works on both the basic science knowledge of how these systems work and also works to create new drugs for human therapy. During our conversation, we discussed: The basics of terpenes. What they are and their role in cannabis The cannabimimetic effects of terpenes and their synergistic effects with cannabinoids What levels of terpenes are needed to get a therapeutic effect A recent study showing terpenes can relieve chronic neuropathic pain Combining terpenes with other drugs, such as opioids, to get better pain relief at lower doses Which terpenes provide the best pain relief Thanks to This Episode's Sponsor: Healer Healer is a trusted, physician-developed medicinal cannabis brand founded to address the challenges of helping people and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer Hemp products are available nationwide and include a step-by-step usage guide and response tracker. Healer's distinctive product formulations and education are based on the latest research and work of leading cannabis clinician, Dr. Dustin Sulak, D.O. Visit Healer.com or HealerCbd.com Additional Resources: Terpenes are Cannabimimetic and Enhance Cannabinoid Activity Terpenes Relieve Chronic Pain A Review Article of Terpenes in Pain A Screen of Minor Cannabinoids in Pain The University of Arizona Comprehensive Center for Pain and Addiction Review the Podcast CannMed Archive

Dr. Harold Han is Chief Science Officer and co-founder of Vertosa, and the pioneer in water compatible cannabinoid ingredients for infused products. Harold designed the industrial leading cannabis emulsions that are widely applied in the cannabis beverage brands. Harold holds 16 patents in emulsion applications, and prior to founding Vertosa, he led a team that developed the emulsification oil for Bio Rad's Digital Droplet PCR system. Harold also publishes a regular series explaining the science of cannabis for product makers under the monicker "The Happy Chemist" — a nickname you'll understand after you watch the interview. One of his recent articles describes the different factors that contribute to cannabis beverage potency loss, which is a challenge for beverage brands. In fact, in regulated markets it's common to see a 10-15% variation in potency compared to the label claim. In unregulated hemp-derived beverages, it can be even higher. During the conversation we discuss The difference between cannabis beverages and alcoholic beverages What happens when cannabinoids oxidize How to put THC into water-based products using physical and chemical processes How every aspect of the supply chain can lead to potency loss in cannabis beverages Which beverage ingredients hasten potency loss How packaging conditions can affect scalping and oxidation rates Thanks to This Episode's Sponsor: Vertosa Vertosa creates industry-leading active ingredients for infused product makers. Their patent-pending nano- and micro-emulsions are carefully designed for the specific needs of each customer, and their pre-suspended aqueous solutions empower them to create incredibly homogenous and stable products while maximizing bioavailability, clarity, and taste. Learn more at Vertosa.com Additional Resources Happy Chemist Article Series The Cannabis Beverage Manufacturing Handbook Review the Podcast CannMed Archive

Dr. Deb Kimless has been in the medical cannabis field since 2013 where her diverse involvement spans many areas including cannabis cultivation, processing, formulation, testing, patient care, and conducting research. She consults within the industry as an advisor for companies who are interested in novel formulations specific to medical conditions, develops protocols, obtains IRB approval, conducts clinical trials, and helps to publish the results. At CannMed 24, Deb presented a poster that shared data from an open-label clinical trial investigating using a cannabinoid-enhanced topical cream for alleviating Restless Leg Syndrome. RLS is condition that affects up to 10% of the US population, including Deb. She found relief using a CBDA-based topical cream and is working with the product manufacturer to conduct clinical trials that demonstrate its effectiveness.  During our conversation, we discuss:  The symptoms of RLS and possible causes  Deb's own struggles with RLS  Why many conventional and pharmaceutical treatments of RLS fall short  Why CBDA appears to be effective at alleviating RLS symptoms  Why a transdermal approach is better than ingesting or inhaling cannabinoids  Results from the open label clinical trial including some remarkable success stories  Thanks to This Episode's Sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more.  Learn more at trustedcannanurse.com  Additional Resources chylorelief.com - USE CODE "CANNMED20" for 20% OFF! Email Deb - dkimless@gmail.com Review the Podcast CannMed Archive

David Aronson is a cannabis educator who since 2018 has directly educated more than 5,000 health professionals nationwide on the medical applications of cannabis. He is on the faculty for PESI, one of the nation's largest providers of professional continuing education, and he independently provides seminars for health professionals nationwide. I learned during our conversation that David also has post-treatment Lyme disease, which is a condition that causes fatigue, neuropathic pain, brain fog, forgetfulness, and other chronic symptoms that he treats with cannabis. His experience made him curious whether others have found success using cannabis to treat persistent Lyme. He shared his findings at CannMed 24 as a poster presentation and with me in the conversation you are about to hear.  We covered:  What is Lyme disease and how does one acquire it The different stages of Lyme disease  Treatments that are available to treat chronic Lyme disease  How David collected data for his study  Which types of products are effective for chronic Lyme symptoms  and more  Thank You to This Episode's Sponsor: McKinney RSA  McKinney is made up of regulatory science veterans who apply lessons learned in the nicotine space to help cannabis manufacturers better understand the toxicological and societal implications of their product.  They do that by Identifying base compounds, extracts, flavors and terpenes, understanding how they interact, and ensuring effectiveness for the intended use. They also provide dosing recommendations and establish guidelines for product consistency.  Learn more at mckinneyrsa.com  Additional Resources lymedisease.org ilads.org strainprint.ca Review the Podcast! CannMed Archive

Zac has been involved in the cannabis industry since 2005. He has had experience with all kinds of growing environments. From outdoor plots in Northern California to warehouses throughout the United States, his journey has taken him to almost every corner of the country. Zac worked at some of the most reputable supply companies and cultivations before landing his job at BioSafe Systems. He is the National Cannabis Specialist for the company, a position that did not exist before Zac was hired. He has comprehensive knowledge of all aspects of cultivation but specializes in integrated pest management (IPM). He has even written the book “Clean Growing: Integrated Pest Management for Cannabis Growers: The Ultimate Guide to Clean Crops & Safe Cultivation Practices That Protect Growers & Consumers” that is available to growers on Amazon. During our conversation we discuss: How Zac got involved with IPM What is IPM and why it's important to cannabis growers How cannabis growers can implement IPM into their operations  Common pests and pathogens that cannabis growers are battling  Common mistakes cannabis growers make when it comes to IPM  and more  Thanks to This Episode's Sponsor: Advanced Nutrients Founded in 1999, Advanced Nutrients was the first to develop a complete nutrient system that unlocks the true genetic potential of the cannabis plant. Since its inception, the brand has introduced more than 50 innovations to the cultivation community, and continues to revolutionize the space through proprietary scientific discoveries.  Learn more at advancednutrients.com  Additional Resources Clean Growing: Integrated Pest Management for Cannabis Growers: The Ultimate Guide to Clean Crops & Safe Cultivation Practices That Protect Growers & Consumers Review the Podcast! CannMed Archive

We will be back with new episodes of the CannMed Coffee Talk Podcast next month! Please be patient as we recharge following the CannMed 24 Innovation and Investment Summit, and prepare for next year's event! Be sure to sign up for email alerts at CannMedEvents.com so you will receive notifications when we publish the CannMed 24 oral presentation videos and announce details for CannMed 25!

Dr. Shannon Smith received his PhD in molecular biosciences from Middle Tennessee State University. There his research focused on plant biotechnology, with work in Cannabis, Panax, and Vitis tissue culture and manipulation. This led to the development of new and unique technologies for the production of both plants and secondary metabolites. He later founded Greenway Lab, a plant biotech company that collaborates with agricultural partners to implement plant biotech solutions to botanical challenges facing the modern agricultural industry. During our conversation, we discuss: How recent advances in plant tissue culture can address major problems faced by the Cannabis industry How rapid, reliable propagation of identical daughter plants can be achieved in tissue culture How long-term storage of explant tissues can be used to regenerate whole plants How developments in meristematic tissue culture protocols can eliminate viral contamination of plant tissues And more! Additional Resources Greenwaylab.co dr.smith@gwlabtn.com Medical Cannabis and Industrial Hemp Tissue Culture: Present Status and Future Potential Cryopreservation of 13 Commercial Cannabis sativa Genotypes Using In Vitro Nodal Explants Initiation, growth and cryopreservation of plant cell suspension cultures ELIMINATION OF HOP LATENT VIROID FROM HOP PLANTS BY COLD TREATMENT AND MERISTEM TIP CULTURE Under siege: virus control in plant meristems and progeny

Tim Lefever is the Director of Discovery at Nalu Bio. He is an experienced Director with a demonstrated history of 20+ years of preclinical in vivo research and leading effective teams at organizations such as Canopy Growth and Research Triangle Institute. He has authored or co-authored numerous manuscripts and presented research findings at a variety of scientific conferences over the past 20 years. At CannMed 24, Tim will present "Characterization of Less Studied Cannabis Phytochemicals” which investigates the pharmacological, physicochemical, and basic toxicological characteristics of cannabis phytochemicals. During our conversation, we discuss: How Tim and his team choose which phytochemicals to study What makes the varin cannabinoids particularly interesting The difference between chemically derived compounds vs plant-derived compounds Which phytochemicals show the most promise Modifying phytochemicals to improve their effectiveness Thanks to This Episode's Sponsor: Brains Bioceutical Brains Bioceutical is a global leader in EU-GMP-certified production of naturally-sourced active pharmaceutical ingredients for the pharmaceutical and nutraceutical industries. With a unique suite of licences, Brains Bioceutical is one of the only natural plant-based phytochemical API manufacturers in commercial production today, and is involved in academic and clinical trials across the globe. Learn more at brainsbioceutical.com Additional Resources nalubio.com Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive

Dr. Kimberly Gwinn is a Professor of Entomology and Plant Pathology at the University of Tennessee. Her lab currently investigates natural products that are produced by plants and microbes and their uses as medicines and as bio-pesticides.  At CannMed 24 she will present Hemp Processing by-products as Biopesticides which describes her team's work using terpene-rich industrial hemp by-products to control plant diseases and pests.  We discuss:  Why terpenes are effective biopesticides  Which pathogens and pests terepene-rich biopesticide can fight  What are nanaemulsions and why they are important in this application  How this technology can open up a new revenue stream for growers  The regulatory lift for getting biopesticides approved  and more  Thanks to this episode's Sponsor: Rare Earth Genomics.  Rare Earth Genomics is a dynamic partnership formed with Texas A&M AgriLife, one of the world's leading research institutions, to accelerate hemp research and create tools for farmers. Their mission is to increase the likelihood of a successful harvest for farmers through genetic analysis and rigorous environmental testing of vigorous cultivars.  learn more at rareearchgenomics.com  Additional Resources Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive

Megan Mbengue is the revolutionary force behind Trusted Canna Nurse. Recognizing a gap between elderly patients and cannabis, Megan sought to provide that demographic with the extra hand-holding and guidance they need to have the best possible experience. With over a decade of nursing experience in diverse fields like oncology, labor delivery, and hospice care, she brings a unique perspective to her practice. At CannMed 24 Megan will be participating in a Cannabis Nursing Panel and presenting a poster titled “Microdosing Psilocybin for Cannabis Dependency: A Nurse Led Intervention”  During our conversation, we discuss:  The important role nurses play in cannabis medicine How brands can tap into the expertise cannabis nurses have How psilocybin can be used to treat addictive behavior  The results from Trusted Canna Nurses 6-week beta for using psilocybin to treat cannabis dependency  and more  Thanks to This Episode's Sponsor: Trusted Canna Nurse Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more.  Learn more at trustedcannanurse.com  Additional Resources Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive

TJ Martin is the VP of R&D at Abstrax, a company that specializes in the research, development, and production of botanically derived and cannabis-inspired terpenes.  TJ and his team recently published a paper that identified several non-terpenoid compounds that are responsible for the unique aromas associated with exotic cannabis varieties, including the berry, tropical, candy, and fruity notes found in Zkittlez and Gelato as well as the rich, intense, chemical scents found in GMO. This research opens up a new world of aromatic compounds and challenges the idea of classifying cultivars based on terpenes alone.  We discuss: How cannabis aroma affects consumer and patient experience  The variety of aromas the cannabis plant can produce and how it compares to other plants  Define exotic cannabis varieties and compare them to more prototypical cultivars  Why terpenes alone do not tell the entire aroma story in exotic cannabis varieties  How to communicate information about non-terpeninoid compounds to consumers and patients in a meaningful way  Thanks to This Episode's Sponsor: Agilent Technologies Whether you manufacture or test cannabis, you face the challenge of delivering high-quality products, increasing sample volume, and meeting emerging regulations. Agilent offers best-in-class cannabis and hemp analysis solutions featuring robust instruments, software, services, and consumables. Their team of experts can develop, implement, and optimize methods to get you up and running quickly. Learn more at agilent.com Additional Resources Minor, Nonterpenoid Volatile Compounds Drive the Aroma Differences of Exotic Cannabis Abstraxtech.com  [Podcast] Discovering New Aromatic Compounds in Cannabis with TJ Martin Cannasulfur Compounds: A New Class of Secondary Metabolites Discovered in Cannabis Cannabis Aroma Predicts User Experience with Adie Rae, PhD The Nose Knows: Aroma, but Not THC Mediates the Subjective Effects of Smoked and Vaporized Cannabis Flower Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive

Dr. Dustin Sulak is a traditional osteopathic physician and expert in integrative medicine. His clinical practice in Maine focuses on treating refractory conditions in adults and children. Dr. Sulak is an internationally-renowned expert in medical cannabis, the author of Handbook of Cannabis for Clinicians: Principles and Practice, and co-founder of Healer, a medical cannabis education resource and products company. He serves on the board of directors of The Society of Cannabis Clinicians and is a passionate educator and leader in the medical cannabis field. Dustin is also a true CannMed veteran, having participated in every CannMed event dating back to our first conference at Harvard Medical School. He returns to CannMed 24 this year as one of the medical practicum instructors and an oral presenter, presenting “The Art and Science of Combining Cannabinoids for Treatment Success” * We discuss: What attendees can expect from CannMed Medical Practicum The expansion of avialble cannabinoids and how Dustin evaluates new options Which Cannabinoid Dustin would choose if he could only use one to treat patients The difference between acidic and neutral forms of cannabinoids The process for combining cannabinoids Challenging old assumptions about the benefits of combining CBD and THC Thanks to This Episode's Sponsor: Healer Healer is a trusted, physician-developed medical cannabis brand founded to address the challenges of helping patients and health providers get the best results with safe, reliably dosable products and education on how to best use them. Healer's distinctive product formulations and educational material are based on the work of leading cannabis clinician, Dr. Dustin Sulak, D.O. Learn More at healer.com Additional Resources Healer.com Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive

Dr. Ethan Russo is a board-certified neurologist, psychopharmacologist, and Founder/CEO of CReDO Science. He is an internationally recognized authority on cannabis medicine. He has authored/edited seven books and has published more than 60 peer-reviewed articles. He also holds director/advisor positions with several cannabis therapeutics companies, and he was instrumental in developing Sativex® for pain and MS, and Epidiolex® for intractable epilepsy while at GW Pharmaceuticals. At CannMed 24, Ethan will present “Cannabinoid Hyperemesis Syndrome (CHS): Unraveling the Gordian Knot”. CHS is an enigmatic condition where some chronic, heavy users of THC develop a cyclic pattern of vomiting and nausea that is only relieved by hot bathing and topical capsaicin. Ethan and his coinvestigators surveyed more than 500 cannabis users, including 205 diagnosed CHS patients, and investigated genetic mutations in 28 CHS patients and 12 controls to identify behaviors and genetic markers that could indicate CHS risk. During our conversation, we discuss:  What is CHS and who does it affect  Why cases of CHS appear to be on the rise  Possible genetic markers that could indicate CHS susceptibility     Steps cannabis users can take to prevent developing CHS  Why some people in the cannabis community don't believe CHS is a real thing and more  Thanks to This Episode's Sponsor: Cannabis Nurses Network Established in 2015, the Cannabis Nurses Network™ is a professional nursing and professional development organization for nurses around the globe. By educating nurses on the science behind the plant and providing a global nursing network, nurses are supported and empowered to implement their knowledge within their community. Learn more at cannabisnursesnetwork.com Additional Resources what-is-chs.com ethanrusso.org CReDO-science.com Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation Unraveling the Mystery of Cannabinoid Hyperemesis Syndrome - CannMed 2019 Panel Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive

Akeem Gardner is the Founder and CEO of Canurta. He is an innovative entrepreneur with over five years of experience in industrial hemp enterprises. He has a proven track record in leading high-performance teams that work across multi-channel platforms and strategically aligning profitability with sustainability and economic development in Ontario. At CannMed 24 Akeem will present Effect of Cannflavins on Mitigating a Motor Neuron Disease. During our conversation we discuss: The minor molecules found in cannabis that Canurta is investigating for therapeutics Canurta's process for evaluating indications for cannflavins and polyphenols How the diverse molecules in cannabis make it a great therapeutic for multifactoral diseases like ALS The potential for cannflavins and polyphenols may be used as a anti-inflammatory nutraceutical and more Thanks to This Episode's Sponsor: American Cannabis Nurses Association ACNA is a national nursing organization whose mission is to advance excellence in cannabis nursing practice through advocacy, collaboration, education, research, and policy development. Founded in 2010, ACNA continues to work on providing its members with up-to-date cannabis information and resources to care for patients who use cannabis. Join them today at cannabisnurses.org and be a part of the change. Additional Resources Akeem on LinkedIn - Email Akeem at Akeem@Canurta.com Canurta Journal Page Register for CannMed 24 What Makes CannMed Unique and Why You Don't Want to Miss It Review the Podcast! CannMed Archive

Kevin McKernan is the Chief Scientific Officer and Founder of Medicinal Genomics. Kevin has pioneered the genomics of cannabis and hemp to build a stronger scientific environment for the study of cannabis based therapeutics and blockchain technologies for tracking and verifying cannabis genetics. At CannMed 24 he will present “Understanding the Prevalence and Risks Associated with Endotoxins on Cannabis Flower”, which will include novel research he did to measure the level of endotoxins in store-bought cannabis flower. Our conversation covers: What inspired Kevin to look into endotoxin levels on cannabis Which microbes produce endotoxins How endotoxins affect humans Whether remediation techniques mask endotoxin risks and more Thanks to This Episode's Sponsor: Agilent Technologies. Whether you manufacture or test cannabis, you face the challenge of delivering high-quality products, increasing sample volume, and meeting emerging regulations. Agilent offers best-in-class cannabis and hemp analysis solutions featuring robust instruments, software, services, and consumables. Their team of experts can develop, implement, and optimize methods to get you up and running quickly. Learn more at agilent.com Additional Resources High levels of endotoxins in commercial cannabis flower [Pre-Print] Total Yeast and Mold - A Comparison Study - Jini Glaros [CannMed 23 Presentation] What Makes CannMed Unique and Why You Don't Want to Miss It Register for CannMed 24 Review the Podcast! CannMed Archive

David Traylor is Senior Managing Director at Golden Eagle Partners, and organizer of the CannMed 24 Capital Markets Workshop. After advising on various transactions in the life science sector, David took an interest in the cannabis sector and started advising cannabis companies before eventually re-foundeding Golden Eagle Partners in 2014 to focus on advising companies across the cannabis sector. Before Golden Eagle Partners, David served at leading investment banking firms including Pacific Growth Equities, Caris & Company, and Headwaters MB. During his banking tenures he has advised private and public biotechnology and medical device companies in various transactions including IPOs, public offerings, private offerings, mergers and acquisitions totaling over $500 million in value. David and Golden Eagle Partners will host a Capital Markets Workshop at CannMed 24 which will explore a global perspective of the hurdles, issues, and concepts around funding cannabinoid and cannabis innovation.  During our conversation we discuss: What attendees can expect from the Capital Markets Workshop Redefining the cannabis nomenclature The likelihood the DEA will reschuelde cannabis this year Pharma's growing interest in cannabis-derived compounds Challenges cannabis innovators face when raising capital Thanks to This Episode's Sponsor: Golden Eagle Partners Golden Eagle Partners are transactional experts, specializing in mergers, acquisitions, reverse mergers, financings and incremental transactions such as licensing, joint ventures and co-development arrangements. Their combined experience in the early stages of the cannabis and life science sectors allows them to confidently close strategic and financing transactions that match the near- and long-term goals of their clients. Learn more at goldeneaglepartners.com  Additional Resources Reclassifying Cannabis: What The HHS Recommendation Means For The Cannabis Market [Benzinga Podcast] David Traylor on LinkedIn Register for CannMed 24 Review the Podcast! CannMed Archive

Bonni Goldstein is one of the country's most respected and experienced medical cannabis physicians, having treated thousands of patients with medical cannabis. She is the owner and medical director of Canna-Centers Wellness & Education. She is Clinical Advisor to Cannformatics, and she is the author of the book titled “Cannabis is Medicine: How Medical Cannabis and CBD Are Healing Everything from Anxiety to Chronic Pain”.  Bonni has participated in every CannMed event since we started in 2016, she is a perennial Advisory Board Member, and she will lead the CannMed Medical practicum again in 2024. During our conversation we talked about:  What attendees can expect from CannMed Medical Practicum New research that she is excited about concerning THCA and CBDA  Her method for customizing cannabinoid formulations for her patients   The many barriers preventing patients from using cannabis  How the cannabinoid medicine options have expanded over the last decade  The difficulty of keeping up with the cannabis medicine literature  Thank You to This Episode's Sponsor: The DENT Institute With more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson's, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute. Learn more at dentinstitute.com Additional Resources Cannabis is Medicine by Bonni Goldstein, MD [Book] @bonnigoldsteinmd on Instagram Bonni Goldstein, MD on LinkedIn Request an Invitation to CannMed 23 Review the Podcast! CannMed Archive CannMed Community Board [Facebook Group] Healthcare Provider Medical Cannabis Research Study

Dr. Patricia DiCiano is a scientist with the Institute for Mental Health and Policy Research at the Centre for Addiction and Mental Health (CAMH). She is also an assistant professor in the Department of Pharmacology and Toxicology at the University of Toronto. Patricia has a multi-disciplinary background and her general research area is clinical trials and regulated studies into the safety of cannabis and other substances of abuse. Earlier this year, she co-authored a study that evaluated the utility of THC cutoff levels in blood and saliva for the detection of impaired driving.  During our conversation, we discussed:  The different allowable limits for THC levels in drivers  The relationship between THC levels and impaired driving  The best fluid to test for THC impairment  The additive effects of combining alcohol and cannabis on driving impairment  The differences in how alcohol and cannabis affect driving performance   Thanks to this episode's sponsor: Trusted Canna Nurse  Trusted Canna Nurse was founded by Megan Mbengue and Ariane Williams, two nurses who are dedicated to bridging the gap between traditional medicine and the world of cannabis and psychedelics. They specialize in creating evidence-based treatment plans for all ages that address chronic illnesses, treatment-resistant conditions, mental health, autism, and more.  Learn more at trustedcannanurse.com  Additional Resources The Utility of THC Cutoff Levels in Blood and Saliva for Detection of Impaired Driving Canadian Cannabis Survey The “Next Day” Effects of Cannabis Use: A Systematic Review Register for CannMed 24 Review the Podcast! CannMed Archive

Dr. Karla Gage is Assistant Professor of Weed Science and Plant Biology at Southern Illinois University Carbondale, where she received her Ph.D. in Plant Biology with a focus in Weed Ecology in 2013. In short, Karla is a weed expert, but not in the weed you smoke, but rather the weeds you pull. Her research focuses on using Integrated Weed Management to control and suppress weeds in midwestern US rotational crops, including corn, soybean, wheat, sorghum, and now hemp.  During our conversation we discussed:  What negative effects weeds can have on hemp  Which weed species are threatening to hemp  Herbicides that are approved for hemp and the threat of herbicide resistance  Integrated weed management strategies, such as, crop rotation, cover crops, and chaff lining, plastic coverings, and more  How ferral hemp varieties may have traits to help breed more resistant hemp varieties  Thanks to this Episode's Sponsor: Rare Earth Genomics Rare Earth Genomics Texas is a partnership formed to accelerate hemp research and produce critical tools for the farmer. REG's mission is to increase likelihood of a successful harvest through genetic analysis and rigorous environmental testing of vigorous cultivars. Reliable datasets, analytic tools and stable germplasm are core to the program. Success of the farmer is the goal! Learn more at rareearthgenomics.com

Dr. Laszlo Mechtler is the Chief Medical Officer at the DENT Neurologic Institute, the largest outpatient neuroscience center in the United States. Dr. Mechtler is the Director of the DENT Cannabis Clinic, which has more than 15,000 patients certified through the NYS MMJ program and continues to grow each day.  He has published some of the first major retrospective research trials on Medical Marijuana in Headaches and other neurologic disorders and lectures both nationally and internationally and is recognized as a leader in the fields of Neuroimaging, Headache Medicine, Neuro-Oncology, and Medical Cannabis. Dr. Mechtler is also a member for he CannMed 24 Advisory Board.  During our conversation we discuss:  How the DENT Institute is uniquely positioned to study medical cannabis for a variety of conditions  Results from recent studies conducted at the DENT Cannabis Clinic The challenges of studying cannabis medicine and how a proposed rescheduling could help  The ongoing struggle to convince fellow clinicians and medical associations that medical cannabis is legitimate  Thanks to This Episode's Sponsor: The DENT Institute With more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson's, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute. Learn more at dentinstitute.com Additional Resources Register for CannMed 24 Submit an Abstract for CannMed 24 Review the Podcast! CannMed Archive CannMed Community Board [Facebook Group]

Bill Graham is the Founder of Microcline Tissue Culture, a company that provides tissue culture kits, consulting, and training to cannabis cultivators. With hands-on expertise, he retailed and distributed hydroponics supplies, sourced grow lights globally, created Biojuice nutrients, designed Phresh filter air quality systems, and simplified micropropagation cloning - creating the leading Microclone tissue culture kits in 2005. During our conversation we discussed: The basics of tissue culture Tissue culture as propagation alternative to cloning How mother plants can lead to pathogen infections and loss of vigor Combining tissue culture and qPCR to eliminate pathogens, such as hop latent viroid and more! Thanks to This Episode's Sponsor: Cambium Analytica Cambium Analytica, provides analytical, product development, and quality assurance services for the natural foods, botanical products, natural pharmaceutical, and dietary supplement industries. Cambium is a leading research organization that is focused on leveraging its expertise on drug discovery and method development, to be a research partner of choice for new innovative companies in the burgeoning botanical medicines space. Their focus on applying analytical techniques in combination with sensory, product development, and consumer research is driving advancement in natural product quality and innovation. Learn more at cambiumanalytica.com Additional Resources microclone.com Microclone on YouTube Register for CannMed 24 Submit an Abstract for CannMed 24 Review the Podcast! CannMed Archive CannMed Community Board [Facebook Group]

Some people in the cannabis industry are questioning whether it is appropriate or necessary to test inhaled cannabis products for pathogenic Aspergillus.  Full disclosure, we at Medicinal Genomics sell qPCR testing kits designed to detect pathogenic Aspergillus on cannabis products. We have also published several resources on our website that describe the potential harms that can be caused by inhaling pathogenic Aspergillus spores and cite with more than 2 dozen Aspergilosis cases in cannabis users.  We have also recommended that states that are considering cannabis testing regulations adopt pathogenic Aspergillus testing. Not because we sell Aspergillus tests, but because we want to protect patients.  By almost any measure, cannabis is one of the most safe and effective medicines available. And in many cases, the potential harms that can come from using cannabis are not caused by the plant, but rather contaminants. And although cases are rare, The documented cases describing Aspergillosis deaths from contaminated cannabis vastly outnumber the published clinical risks for every other contaminant for which the cannabis industry tests. There are no documented deaths for cannabis-derived heavy metals, mycotoxins, pesticides or incorrect cannabinoid labeling. The same cannot be said  So that is our position, but of course we acknowledge that we are biased, and we are not experts on pathogenic fungi; however, our guest today is.  David W. Denning is a Professor of Infectious Diseases in Global Health at the University of Manchester in the United Kingdom. He was the founding president, executive director, and CEO of Global Action For Fungal Infections, an organization dedicated to reducing the worldwide burden of fungal disease. In 2016, he became the director of the National Aspergillosis Centre in Manchester, which treats patients with chronic pulmonary aspergillosis (CPA), and led the committee that developed the first CPA guidelines. He chairs the editorial board of a website which focusses on aspergillus and he leads an organisation which provides education on fungal diseases.  In short, Dr. Denning is the leading authority on all things Aspergillus, and we asked him many of the questions that have been debated on social media recently, including:  Should cannabis be tested for pathogenic Aspergillus Should there be an allowable limit for pathogenic Aspergillus? Is Apergillosis only a concern for immunocompromised patients?  Are the number of Aspergillosis cases under reported?  How difficult is Aspergillosis to diagnose and treat?  How ubiquitous is Aspergillus in the air we breathe?  and so much more.  Thanks to This Episode's Sponsor: Modern Canna Modern Canna is regarded as Florida's first medical cannabis laboratory and one of the most trusted third party testing providers in the United States. The company's mission is to help set the standard for cannabis testing labs worldwide by providing the most accurate and efficient testing services, delivered with a sense of compassion, integrity, and moral obligation; and to attract and attain clients who value quality data that is verifiable, reproducible, and legally defensible. Modern Canna is the only Leafly Certified laboratory in the eastern United States and adheres to the industry's strictest SOPs and quality control standards. Modern Canna offers a wide variety of testing, rapid turnaround times, and consulting services to Florida Medical Marijuana Treatment Centers (MMTC's) and hemp businesses throughout the US. Learn more at moderncanna.com Additional Resources Too Many Mouldy Joints – Marijuana and Chronic Pulmonary Aspergillosis The Aspergillus website https://en.fungaleducation.org/ Submit an Abstract for CannMed 24 Review the Podcast! CannMed Archive CannMed Community Board [Facebook Group]

Mitchell Westmoreland is a Ph.D. candidate working with Dr. Bruce Bugbee in the Crop Physiology Laboratory at Utah State University. His Ph.D. research focuses on whole-plant physiology and cultivation of medical Cannabis in controlled environments. He has published his research on photobiology and plant nutrition in high-impact peer-reviewed scientific journals. I spoke with Mitch about the various environmental factors that contribute to cannabis yield, specifically light, temperature, humidity, and CO2. Mitch does a great job explaining the energy cascade, which describes the underlying mechanisms that plants use to convert photons to energy and ultimately biomass. Mitch also explains how those factors can be manipulated to not only increase yield but also make better use of resources. Thanks to This Episode's Sponsor: Advanced Nutrients. Founded in 1999, Advanced Nutrients was the first to develop a complete nutrient system that unlocks the true genetic potential of the cannabis plant. Since its inception, the brand has introduced more than 50 innovations to the cultivation community, and continues to revolutionize the space through proprietary scientific discoveries.  Learn more at advancednutrients.com  Additional Resources Elevated UV photon fluxes minimally affected cannabinoid concentration in a high-CBD cultivar Cannabis lighting: Decreasing blue photon fraction increases yield but efficacy is more important for cost-effective production of cannabinoids Sustainable Cannabis Nutrition: Elevated root-zone phosphorus significantly increases leachate P and does not improve yield or quality An approach to crop modeling with the energy cascade Exploring the Limits of Crop Productivity The Science and Technology of Medical Cannabis Cultivation Utah State University Course Review the Podcast! CannMed Archive CannMed Community Board [Facebook Group]

Danielle McCartney is a Postdoctoral Research Associate at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. Her main role is to coordinate clinical research into the effects of cannabidiol on simulated car driving performance.  Danielle and her colleagues recently published a systematic review of 20 studies that examine the next-day effects of THC. As the study states, “The length of time an individual should wait following cannabis use before performing safety-sensitive tasks, is a critical issue.” Some government agencies and experts recommend individuals avoid performing safety-sensitive tasks for at least 24 hours. It should not surprise you to learn that the data suggests a much shorter impairment window. During our conversation, we discuss: The different types of studies the authors reviewed and the criteria they used to evaluate them The different tests administered to measure impairment How next-day effects of THC compare to acute effects How next-day effects are different in medicinal cannabis patients vs. recreational users What methods are available to determine THC impairment in drivers What is a reasonable impairment window for THC Thank You to This Episode's Sponsor: Medicine Women Health Medicine Women's team of specialists includes Medical Doctors, Naturopaths, Medical Cannabis Experts, Nutritionists and Alternative Health Practitioners. These integrative teams evaluate health issues and design targeted protocols to promote personal healing. Medicine Women's Protocols have successfully alleviated symptoms of Cancer, Auto-Immune Diseases and Neurological Conditions, as well as providing overall Health Rejuvenation. Learn more at www.medicinewomenhealth.com.  Additional Resources The “Next Day” Effects of Cannabis Use: A Systematic Review Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review Lambert Initiative for Cannabinoid Therapeutics Review the Podcast! CannMed Archive CannMed Community Board [Facebook Group]

The CannMed Coffee Talk is on a bit of a break. We will be back with a brand new episode on Wednesday, September 20th.  This hiatus will allow us to upgrade some of our equipment and processes so we can improve our production quality and give us more time between recording the podcast and getting the episodes published. You may have noticed that our last few episodes have included a video element, which adds a whole new layer of complexity to the production.  So hang tight, we already have some great guests lined up that I think you will all enjoy. But in the meantime, we invite you to check out any past episodes you may have missed. They are all available on the CannMed Coffee Talk Podcast page. And please also check out the video recordings of all the past CannMed presentations in the CannMed Video Archive. 

Zamir Punja, PhD is a Professor of Plant Biotechnology at Simon Fraser University in Canada. His research interests include the etiology and management of plant diseases on vegetable and horticultural crops, and the applications of plant biotechnology for disease management. Since 2018, his work has shifted to researching cannabis, where his group has described a range of previously unreported pathogens affecting the crop and has evaluated various methods for disease management. His team just published the results of a 3-year study that identified several factors related to growing, drying, and trimming cannabis that have a direct effect on Yeast and Mold levels. This is important because when growers fail for microbial testing, yeast and mold is most often the reason. So if you are a grower who has struggled with total yeast and mold, perhaps these findings can help you get back on track. I've put a link to the paper in the show description, and if you are watching on YouTube, I have added several figures and images from the paper throughout the conversation. We covered: The different species of yeast and mold that are commonly found on cannabis and which are potentially harmful to humans The value of TYM testing as an indicator of product safety and quality What is a reasonable threshold for Total Yeast and Mold How Cannabis genotype affects TYM levels Why leaf litter drives up TYM levels Why hang drying is a better method than wet trimming The drawbacks of irradiation And more Thanks to This Episode's Sponsor: Agilent Technologies Whether you manufacture or test cannabis, you face the challenge of delivering high-quality products, increasing sample volume, and meeting emerging regulations. Agilent offers best-in-class cannabis and hemp analysis solutions featuring robust instruments, software, services, and consumables. Their team of experts can develop, implement, and optimize methods to get you up and running quickly. Learn more at agilent.com Additional Resources Total yeast and mold levels in high THC-containing cannabis (Cannabis sativa L.) inflorescences are influenced by genotype, environment, and pre-and post-harvest handling practices 5 Factors Causing Cannabis to Fail Total Yeast and Mold Review the Podcast! CannMed Archive CannMed Community Board [Facebook Group]

VIDEO VERSION AVAILABLE ON YOUTUBE Dr. Zamir Punja is a Professor of Plant Biotechnology at Simon Fraser University in Canada. His research interests include the etiology and management of plant diseases on vegetable and horticultural crops, and the applications of plant biotechnology for disease management. Since 2018, his work has shifted to researching cannabis, where his group has described a range of previously unreported pathogens affecting the crop and has evaluated various methods for disease management. Zamir's latest research has been focused on a pathogen that is spreading throughout cannabis cultivation facilities worldwide, Hop Latent Viroid. HLVd is a relatively new pathogen. It was first identified in hops in the late 80s and was detected in cannabis in 2018. It is also quite small, only 40 nanometers in size. Still, in just five years this tiny pathogen has managed to infect as much as 90% of cannabis facilities in California alone. All while reducing yields by as much as 50% and costing the industry $4 billion in losses. Zamir shared his latest research on HLVd at CannMed 23, which is the basis of our conversation today. I have put a link to the video of his presentation in the show description. Our conversation covers: 0:00 Introduction 4:38 Why Zamir calls HLVd the “COVID of Cannabis” 8:06 Evidence that HLVd spreads through seed 10:42 What is it doing to cannabis plants? 13:17 How hop growers dealt with HLVd 16:06 Lack of genetic diversity in HLVd 19:50 Up close view of trichomes on HLVd-infected plants 29:57 Treatment and Remediation options 32:53 HLVd Testing protocols 38:41 Sampling recommendations 48:05 Hope for the Future 50:30 Related Resources 52:47 Outro Thanks to This Episode's Sponsor: PhenoXpress PhenoXpress offers low-cost genetic testing services to cultivation facilities. Using qPCR technology, PhenoXpress helps cutlivators identify genetic traits, such as plant sex, while plants are still in the seedling tray. They can also identify plant pathogens, such as Hop Latent Viroid, Lettuce Chlorosis Virus, and Powdery Mildew before plants show obvious signs of infection. Contact PhenoXpress today so they can help you predict, prevent, and eliminate major crop problems before they happen.  Learn more at phenoxpress.com Additional Resources Understanding and Managing Hop Latent Viroid in Cannabis - Zamir Punja, PhD [CannMed 23 Presentation] Hop Latent Viroid Shares a 19 Nucleotide Sequence with Cannabis sativa COG7 - Kevin McKernan [CannMed 23 Presentation] - Hop Latent Viroid in Cannabis Review the Podcast! CannMed Archive CannMed Community Board [Facebook Group]

Hunter Land, PhD is the Vice President of Research & Development at Biopharmaceutical Research Company, one of the few DEA Schedule I, FDA compliant cannabinoid research and development companies. He has 20 years of R&D expertise across 25 different indications, as well as 12 years of cannabinoid-focused research.  Most notably, he was GW Pharma's first full-time R&D employee in the US, where he played a critical role in the development of Epidiolex® and Sativex®, and co-authored multiple protocols for the treatment of refractory epilepsy, multiple sclerosis, and pain. At CannMed 23, Hunter's presentation was titled Effect of Cannabinoids and Cannflavins on Neurodegeneration, Lifespan, and Healthspan, which is the basis for our conversation today. You can find a link to that video in the show description. Topics we discussed include: Defining lifespan, healthspan, and longevity Why C. elegans are good organisms for studying toxicity and longevity Whe entourage effect, more specifically whether a combination of compounds has a greater effect on longevity than single compounds How do cannabis compounds compare to other longevity drugs like metformin and resveratrol Whether cannabis compounds could be used prophylactically for conditions like Alzheimer's and dementiaDetermining the ideal dosing range for cannabinoids Whether CBD and CBG should be incorporated into a healthy lifestyle to improve longevity  Thanks to This Episode's Sponsor - Trulieve Trulieve strives to bring you the relief you need in a product you can trust. Their plants are hand-grown in a facility with a controlled environment specially designed to reduce unwanted chemicals and pests, keeping the process as natural as possible at every turn. Their mission is to provide compassionate care patients can trust when traditional medicine is not enough. Their specially-trained staff works hand-in-hand with YOUR physician to provide the right products and the correct dosage to ensure you get the compassionate care you need. To learn more visit trulieve.com Additional Resources Effect of Cannabinoids and Cannflavins on Neurodegeneration, Lifespan, and Healthspan - Hunter Land (CannMed 23 Presentation Video) Biopharmaceutical Research CompanyReview the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]

Arnaud Dumas de Rauly is the co-founder and CEO of The Blinc Group, a company that is transforming the cannabis vaping industry with its focus on safety, innovation, and quality. As a leading expert in the science, technology, and supply chain of cannabis vaping merchandise, Arnaud's assistance and expertise in the vaping sector have been requested by multiple regulatory bodies across North America, Europe, and Asia. He currently works pro-bono as Chairman of the ISO, International Organization of Standardization, TC126/SC3 on Vaping Products, and of the CEN Standards Committee TC437 on Vapor Products. He is also a member of the Marijuana Science and Policy Work Group operated by the Colorado Department of Revenue's MED and CDPHE and the ASTM D37 Cannabis Committee. At CannMed 23, Arnaud talked about the many variables that affect how well cannabis vape cartridges deliver cannabinoids to the user. During our conversation, we dig deeper into the following topics:  What should consumers and patients be looking at when choosing vape products? The symbiotic relationship between cannabis oil and vape hardware Why emissions testing is important to understand what the user is inhaling Different cannabinoids have different rates of aerosolization. So much so that they may be completely gone before the oil is. How federal legalization may change cannabis vape regulations and requirements Tips for patients who want to vape their medicine  Thanks to This Episode's Sponsor: The Blinc Group Headquartered in New York City, The Blinc Group designs, manufactures, and provides premium cannabis vaping hardware. The company offers a curated collection of proven cartridges, batteries, ready to use vaporizers and complete bespoke device development to multi-state operators, licensed producers, processors and brands. Blinc completes the value chain by providing its clients access to a suite of services ranging from 5 month financing options, vendor managed inventory (VMI), R&D, production, product testing, standard operating procedures, training and all the way to go-to-market strategy and brand communications consulting. With full control of the supply chain, the company's unique “Powered by Blinc” process enables clients to provide innovative, safe and quality controlled products to cannabis consumers worldwide. To learn more about Blinc, visit http://www.theblincgroup.com Additional Resources A First Look Into Cannabis Vaping Variables & Delivery - Arnaud Dumas de Rauly (CannMed 23 Presentation Video)The Cannabis Vape Consumption SurveyThe Blinc Group websiteReview the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]

In 2022, Dr. Jeff Rawson founded the Institute of Cannabis Science (ICS), a nonprofit organization that produces Honest Data About Weed.  The mission of ICS is to conduct cannabis research that educates consumers, guides regulators to adopt testing regulations that are based on science, and ensures that products are safe for patients and consumers. At CannMed 23 Dr. Rawson will participate in a panel discussion about Challenges with Regulating the Cannabis Industry as part of the CannMed Laboratory Compliance Testing Workshop. In December 2022, he made a presentation entitled Misinformation in Cannabis Markets to the members of the Massachusetts (MA) Cannabis Advisory Board Research Subcommittee.  Jeff has presented recommendations for corrective actions to prevent misinformation in the MA cannabis market.  The Boston Globe has published his letters about the challenges of cannabis regulatory science. During our conversation, we discuss: What the Institute of Cannabis Science is and what they do How the average THC% in Massachusetts flower increased from 2019 to 2022, and what could that be a sign of The information presented to consumers on dispensary websites is limited and vague The challenge of collecting and analyzing cannabis testing data How providing more information on cannabis labels leads to healthier consumers Thanks to This Episode's Sponsor: Brains Bioceutical Brains Bioceutical is a global leader in EU-GMP-certified production of naturally-sourced active pharmaceutical ingredients for the pharmaceutical and nutraceutical industries. With a unique suite of licences, Brains Bioceutical is one of the only natural plant-based phytochemical API manufacturers in commercial production today, and is involved in academic and clinical trials across the globe. Brains Bioceutical is the leader in evidence-based Phyto-cannabinoid health solutions to enhance life and treatment options for all. Learn more at brainsbioceutical.com  Additional Resources Institute of Cannabis Science websiteEye on CannabisRequest an Invitation to CannMed 23Review the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]Healthcare Provider Medical Cannabis Research Study

If you grow or consume cannabis, you've benefited from something Michael Straumietis has done. A grower since 1983, Michael's mission is to make cannabis an acceptable and everyday part of healing humanity. In 1999, he founded Advanced Nutrients and launched the world's first and only complete cannabis growing system that Hits the Shift and optimizes all phases of the vegetative and bloom cycles to bring cannabis to its true genetic potential. At CannMed 23, Michael is leading the Cultivation Workshop that focuses on fighting profit-robbing plant pathogens, such as hop latent viroid (HLVd), fusarium, botrytis, pythium, powdery mildew, and Phytophthora. The workshop brings together industry-leading experts who will cover both efficient and economically sound practices for pathogen management, so you can maximize ROI in your cultivation facility. Get ready to explore the science behind each major pathogen, vectors through which they infiltrate facilities and plants, and proven methods for pathogen prevention. We'll also introduce effective strategies for pathogen detection, as well as critical procedures to implement for continued facility success before, during, and after a pathogen occurrence. During our conversation, we discuss: How plant pathogens can impact growers' bottom lines The emergence of new pathogens and where they may have come fromThe importance of early detection Preventing plant pathogens with good SOPsNew Advanced Nutrients products aimed at helping growers combat pathogens  Thanks to This Episode's Sponsor: Advanced Nutrients Founded in 1999, Advanced Nutrients was the first to develop a complete nutrient system that unlocks the true genetic potential of the cannabis plant. Since its inception, the brand has introduced more than 50 innovations to the cultivation community, and continues to revolutionize the space through proprietary scientific discoveries.  Learn more at advancednutrients.com BigMike on InstagramChat with Buddy on advancednutrients.comRequest an Invitation to CannMed 23Review the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]Healthcare Provider Medical Cannabis Research Study

Dr. Bonni Goldstein is one of the country's most respected and experienced medical cannabis physicians, having treated thousands of patients with medical cannabis. She is the owner and medical director of Canna-Centers Wellness & Education. She is Clinical Advisor to Cannformatics. And she is the author of the book titled “Cannabis is Medicine: How Medical Cannabis and CBD Are Healing Everything from Anxiety to Chronic Pain”.  Bonni is leading the CannMed Medical practicum this year and also presenting about Minor Cannabinoids during the main session. During this episode we dive into one of those cannabinoids, CBG, and discuss the following:  What makes CBG one of Bonni's favorite new cannabinoids What makes CBG a “bridge” cannabinoid between THC and CBD The difference between CBGA and CBG How CBG enhances the body's natural endocannbinoid system How CBG works in combination with other cannabinoids Conditions for which CBG is a good fitPotential adverse reactions to CBG A preview of the CannMed Medical Practicum  Thanks to This Episode's Sponsor: The DENT Institute With more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson's, Dementia, Neuro-Oncology, etc. With our mission of advancing neuroscience, we established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout our institute. Learn more at dentinstitute.com Additional Resources What is CBG [YouTube Video]@bonnigoldsteinmd on InstagramBonni Goldstein, MD on LinkedInRequest an Invitation to CannMed 23Review the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]Healthcare Provider Medical Cannabis Research Study

Anthony Repay is currently serving as Laboratory Director of Method Testing Laboratories in Tampa, FL. Anthony started his career as the head food and environmental microbiologist at a Chicago-based testing laboratory before joining the cannabis science community. Since joining cannabis, Anthony has tried to innovate and push the cannabis microbiology community by publishing peer-reviewed papers, speaking on proper quality control and volunteering in several national wide cannabis groups.  During our conversation we discuss: How growers can incorporate microbial testing into their processes Sources of microbial contamination and tips for prevention How differences in microbial regulations influence growers in certain states Remediation technologies and more  Thanks to This Episode's Sponsor: RS BioTherapeutics  RS BioTherapeutics' first investigational compound (RSBT-001) is a nebulized, semi-synthetic, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases including COPD, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. More information on RS BioTherapeutics can be found at www.rsbiotherapeutics.com. Additional Resources Anthony Repay on LinkedInMethod Testing Laboratories websiteCannabis Microbial Testing Regulations by State [Interactive Tool]Request an Invitation to CannMed 23Review the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]Healthcare Provider Medical Cannabis Research Study

Dr. Russel Jessup is an Associate Professor at Texas A&M University. Russ started his career developing improved perennial grasses as biorefinery platforms for biofuels, turfgrasses, forage, ornamentals, phytoremediators, and renewable bio-based products. He has since transitioned into working on breeding industrial hemp, during which, he and his team identified a need for field-portable testing technologies that could help accelerate their programs. At CannMed 23, he will present on three of those technologies. Doing our conversation we discuss:  How a field portable near-infrared spectrometer can be used to screen hemp plants to make sure they don't exceed 0.3% THC How a cellphone-based microscope attachment can determine the size, maturity, and type of trichomes How a microfluid channels are used to identify tetraploid hemp plants, which produce better fiber and grain than diploid plants How microfiber tents contain pollen from male plants so they can be in the same room as females Why Russ moved from perennial grasses to hemp The goal of creating stable, consistent industrial hemp lines that can be grown like other modern major crops   Thanks to This Episode's Sponsor: Rare Earth Genomics Rare Earth Genomics Texas is a partnership formed to accelerate hemp research and produce critical tools for the farmer. REG's mission is to increase likelihood of a successful harvest through genetic analysis and rigorous environmental testing of vigorous cultivars. Reliable datasets, analytic tools and stable germplasm are core to the program. Success of the farmer is the goal! Additional Resources Russell Jessup on LinkedInHemp Conversion ProgramRequest an Invitation to CannMed 23Review the Podcast!CannMed ArchiveCannMed Community Board [Facebook Group]Healthcare Provider Medical Cannabis Research Study